BioCryst Shares Remain Undervalued, RBC Says

MT Newswires Live03-25

BioCryst Pharmaceuticals (BCRX) remains undervalued even with a recent price increase due to unconfirmed reports of being a takeover target, RBC Capital Markets said in a Wednesday note.

Even with the shares up 24% year-to-date, RBC's analysis of BioCryst in various takeout scenarios and as an independent company all projected share prices that are higher than what they are currently. The scenarios made various assumptions about the peak revenue for the company's hereditary angioedema treatments Orladeyo and Navenibart, as well as the potential discounted cash flow takeout value.

RBC analysts said their analysis forecast the company's share price at $18 per share in the base case, $20 per share in the bull case, and $12 per share in the bear case.

Even with the potential impact of rival Pharvaris' (PHVS) Q3 data for its competing hereditary angioedema drug, Orladeyo is still likely to have a "meaningful" role in disease treatment, while Navenibart could see a growing role among the longer-acting prophylactic injectables, the report said.

RBC kept its outperform rating with a price target of $13.

Price: 9.57, Change: -0.10, Percent Change: -0.98

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2622107082?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-03-25 23:18","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2622107082","market":"us","top_or_hot":-1,"title":"BioCryst Shares Remain Undervalued, RBC Says","media":"MT Newswires Live","content":"<html><body><p> BioCryst Pharmaceuticals (BCRX) remains undervalued even with  a recent price increase due to unconfirmed reports of being a takeover target, RBC Capital Markets said in a Wednesday note.</p><p>Even with the shares up 24% year-to-date, RBC's analysis of BioCryst in various takeout scenarios and as an independent company all projected share prices that are higher than what they are currently. The scenarios made various assumptions about the peak revenue for the company's hereditary angioedema treatments Orladeyo and Navenibart, as well as the potential discounted cash flow takeout value.</p><p>RBC analysts said their analysis forecast the company's share price at $18 per share in the base case, $20 per share in the bull case, and $12 per share in the bear case.</p><p>Even with the potential impact of rival Pharvaris' (PHVS) Q3 data for its competing hereditary angioedema drug, Orladeyo is still likely to have a \"meaningful\" role in disease treatment, while Navenibart could see a growing role among the longer-acting prophylactic injectables, the report said.</p><p>RBC kept its outperform rating with a price target of $13.</p><p>Price: 9.57, Change: -0.10, Percent Change: -0.98</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BioCryst Shares Remain Undervalued, RBC Says</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBioCryst Shares Remain Undervalued, RBC Says\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2026-03-25 23:18</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> BioCryst Pharmaceuticals (BCRX) remains undervalued even with  a recent price increase due to unconfirmed reports of being a takeover target, RBC Capital Markets said in a Wednesday note.</p><p>Even with the shares up 24% year-to-date, RBC's analysis of BioCryst in various takeout scenarios and as an independent company all projected share prices that are higher than what they are currently. The scenarios made various assumptions about the peak revenue for the company's hereditary angioedema treatments Orladeyo and Navenibart, as well as the potential discounted cash flow takeout value.</p><p>RBC analysts said their analysis forecast the company's share price at $18 per share in the base case, $20 per share in the bull case, and $12 per share in the bear case.</p><p>Even with the potential impact of rival Pharvaris' (PHVS) Q3 data for its competing hereditary angioedema drug, Orladeyo is still likely to have a \"meaningful\" role in disease treatment, while Navenibart could see a growing role among the longer-acting prophylactic injectables, the report said.</p><p>RBC kept its outperform rating with a price target of $13.</p><p>Price: 9.57, Change: -0.10, Percent Change: -0.98</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4547","symbol_name":"WSB热门概念","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2622107082","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2622107082","pubTimestamp":1774451926,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"BioCryst Pharmaceuticals  remains undervalued even with  a recent price increase due to unconfirmed reports of being a takeover target, RBC Capital Markets said in a Wednesday note.Even with the shares up 24% year-to-date, RBC's analysis of BioCryst in various takeout scenarios and as an independent company all projected share prices that are higher than what they are currently. The scenarios made various assumptions about the peak revenue for the company's hereditary angioedema treatments Orladeyo and Navenibart, as well as the potential discounted cash flow takeout value.RBC analysts said their analysis forecast the company's share price at $18 per share in the base case, $20 per share in the bull case, and $12 per share in the bear case.Even with the potential impact of rival Pharvaris'  Q3 data for its competing hereditary angioedema drug, Orladeyo is still likely to have a \"meaningful\" role in disease treatment, while Navenibart could see a growing role among the longer-acting pro","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4547":"WSB热门概念","PHVS":"Pharvaris N.V.","BCRX":"BioCryst制药","BK4139":"生物科技","BK4007":"制药"},"translate_title":"加拿大皇家银行表示，BioCryst股价仍然被低估","themeId":"f6f7c9f6a0174df79daf9f1dfd21f836","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"BCRX":1,"PHVS":1},"content_text":"BioCryst Pharmaceuticals (BCRX) remains undervalued even with  a recent price increase due to unconfirmed reports of being a takeover target, RBC Capital Markets said in a Wednesday note.Even with the shares up 24% year-to-date, RBC's analysis of BioCryst in various takeout scenarios and as an independent company all projected share prices that are higher than what they are currently. The scenarios made various assumptions about the peak revenue for the company's hereditary angioedema treatments Orladeyo and Navenibart, as well as the potential discounted cash flow takeout value.RBC analysts said their analysis forecast the company's share price at $18 per share in the base case, $20 per share in the bull case, and $12 per share in the bear case.Even with the potential impact of rival Pharvaris' (PHVS) Q3 data for its competing hereditary angioedema drug, Orladeyo is still likely to have a \"meaningful\" role in disease treatment, while Navenibart could see a growing role among the longer-acting prophylactic injectables, the report said.RBC kept its outperform rating with a price target of $13.Price: 9.57, Change: -0.10, Percent Change: -0.98","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.40.0","shortVersion":"4.40.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2622107082","isCrawlerRequest":true}